Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 9/20 | 0.41 |
| ▸ | DNMT3B | Q9UBC3 | 4/20 | 0.39 |
| ▸ | FPR2 | P25090 | 2/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13475068 | 0.93 | DNMT1 (0.41) | DNMT1DNMT3BFPR2ADRB1 | |
| SCHEMBL16731433 | 0.92 | DNMT1 (0.40) | DNMT1DNMT3BFPR2ADRB1 | |
| SCHEMBL2065719 | 0.90 | P2RY2 (0.36) | DNMT1 | |
| SCHEMBL10178137 | 0.89 | CA2 (0.36) | DNMT1DNMT3BFPR2 | |
| SCHEMBL10178240 | 0.88 | LMNA (0.31) | DNMT1 | |
| SCHEMBL2065887 | 0.88 | TK1 (0.42) | — | |
| SCHEMBL2065883 | 0.88 | TK1 (0.42) | — | |
| SCHEMBL12762684 | 0.88 | TK1 (0.42) | — | |
| SCHEMBL14778032 | 0.88 | TK1 (0.42) | — | |
| SCHEMBL12570204 | 0.88 | TK1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148503-B2 | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100041041-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041041-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | UNG, NT5C2, NT5E | DNMT1 55/4885DNMT3B 69/4885FPR2 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.